The promise of Immuno-oncology: implications for defining the value of cancer treatment

Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape

(2019) Neeraja Dharmaraj et al.   OncoImmunology

Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols

(2018) Melanie Calvert et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Patient-reported outcomes in PD-1/PD-L1 inhibitor registration trials: FDA analysis of data submitted and future directions.

(2018) Lynn Jackson Howie et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]

(2018) Darius N. Lakdawalla et al.   VALUE IN HEALTH

A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]

(2018) Louis P. Garrison et al.   VALUE IN HEALTH

ISPOR’s Initiative on US Value Assessment Frameworks: A Missed Opportunity for ISPOR and Patients

(2018) Eleanor M. Perfetto   VALUE IN HEALTH

Patient Access to Medicines for Rare Diseases in European Countries

(2018) Andreja Detiček et al.   VALUE IN HEALTH

Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group

(2018) Sandra Nestler-Parr et al.   VALUE IN HEALTH

Review of Recent US Value Frameworks—A Health Economics Approach: An ISPOR Special Task Force Report [6]

(2018) Richard J. Willke et al.   VALUE IN HEALTH

DIFFERENTIATION OF HEALTH-RELATED QUALITY OF LIFE OUTCOMES BETWEEN FIVE DISEASE AREAS: RESULTS FROM AN INTERNATIONAL SURVEY OF PATIENTS

(2018) Olina Efthymiadou et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Future Directions for Cost-effectiveness Analyses in Health and Medicine

(2018) Peter J. Neumann et al.   MEDICAL DECISION MAKING

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

(2018) Sunilkumar Kakadia et al.   OncoTargets and Therapy

Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology

(2018) Bruno Kovic et al.   JAMA Internal Medicine

Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia

(2018) Melanie D. Whittington et al.   JAMA Pediatrics

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy

(2018) Paolo A. Ascierto et al.   JAMA Oncology

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

(2017) Leisha A. Emens et al.   EUROPEAN JOURNAL OF CANCER

Patient value: Perspectives from the advocacy community

(2017) Bonnie J Addario et al.   HEALTH EXPECTATIONS

Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment

(2017) Ethan Basch et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Value to Whom? The Patient Voice in the Value Discussion

(2017) Eleanor M. Perfetto et al.   VALUE IN HEALTH

Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks

(2017) Joshua T. Cohen et al.   VALUE IN HEALTH

Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs

(2017) Tanya G.K. Bentley et al.   VALUE IN HEALTH

Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review

(2017) Da-Ping Yu et al.   Oncology Letters

The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting

(2017) Howard L. Kaufman et al.   Journal for ImmunoTherapy of Cancer

Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients

(2016) Vakaramoko Diaby et al.   CURRENT MEDICAL RESEARCH AND OPINION

Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives

(2016) Markus Moehler et al.   EUROPEAN JOURNAL OF CANCER

Doxorubicin and cisplatin induce apoptosis in ovarian stromal cells obtained from cryopreserved human ovarian tissue

(2016) Raffaella Fabbri et al.   Future Oncology

Toward a Patient-Centered Value Framework in Oncology

(2016) Ethan Basch   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

(2016) Gillian D. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards

(2016) Andrew Bottomley et al.   LANCET ONCOLOGY

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them

(2016) Kerry J. Savage et al.   Expert Review of Hematology

Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy

(2016) K. Okkenhaug et al.   Cancer Discovery

The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis

(2016) BaSang CiRen et al.   Oncotarget

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

(2015) N. I. Cherny et al.   ANNALS OF ONCOLOGY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Continuous Patient Engagement in Comparative Effectiveness Research

(2012) Abdulla M. Abdulhalim   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Modeling Good Research Practices—Overview

(2012) J. Jaime Caro et al.   MEDICAL DECISION MAKING

Defining Comparative Effectiveness Research

(2010) Harold C. Sox   MEDICAL CARE

Retaining, and Enhancing, the QALY

(2009) Joseph Lipscomb et al.   VALUE IN HEALTH